Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages

  Law, Lisa Y ^a  

^a Woodland Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; THYROID TRANSCRIPTION FACTOR 1; TRASTUZUMAB;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CASE REPORT; CHROMOSOME 17; COUGHING; DYSPNEA; FEMALE; GALLBLADDER CARCINOMA; GENE AMPLIFICATION; HOSPICE CARE; HUMAN; HYPERMETABOLISM; LUNG INFILTRATE; LUNG METASTASIS; LUNG NODULE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SHOULDER PAIN; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PACLITAXEL; RECEPTOR, ERBB-2; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84866771822     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.3061     Document Type: Article

References (16)

1. Khan SA, Thomas HC, Davidson BR, et al: Cholangiocarcinoma. Lancet 366:1303-1314, 2005 (Pubitemid 41416587)
2. Sirica AE: Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5-15, 2005
3. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281, 2010
4. Olayioye MA, Neve RM, Lane HA, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000 (Pubitemid 30428195)
5. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001 (Pubitemid 33674041)
6. Vogel CL, Cobleigh MA, Tripathy D, et al: First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61:37-42, 2001 (suppl 2)
7. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
8. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
9. Aishima SI, Tagucki KI, Sugimachi K, et al: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40:269-278, 2002 (Pubitemid 34227118)
10. Ito Y, Takeda T, Sasaki Y, et al: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197:95-100, 2001 (Pubitemid 32194502)
11. Ukita Y, Kato M, Tereda T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (Her-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 36:780-785, 2002 (Pubitemid 35177407)
12. Yoshikawa D, Ojima H, Iwasaki M, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:418-425, 2008 (Pubitemid 351161240)
13. Zhang A, Sirica AE: Simultaneous inhibition of ErbB1 and ErbB2 signaling significantly enhances the growth suppression of rat and human cholangiocarcinoma cell lines. FASEB 21:A71-A72, 2007
14. Treekitkarnmongkol W, Suthiphongchai T: High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol 16:4047-4054, 2010
15. Ramanathan RK, Belani CP, Singh DA, et al: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer HCC): A California Consortium (CCC-P) Trial. J Clin Oncol 24:181s, 2006 (suppl 15; abstr 4010)
16. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al: Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 13:4495-4502, 2007 (Pubitemid 47219719)